HEPION PHARMACEUTICALS, INC.: 10-Q filed 2015-05-14
What HEPION PHARMACEUTICALS, INC. reported in its quarterly report filed 2015-05-14 (fiscal Q3 2015): 20 published measures, 51 facts as tagged in accession 0001104659-15-037966.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2015-05-14
- Fiscal period
- fiscal Q3 2015
- Accession
- 0001104659-15-037966 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All HEPION PHARMACEUTICALS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 9,499,550 | USD | |
| At 2014-06-30 | 2,000,904 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 1,615,697 | USD | |
| At 2014-06-30 | 4,934,084 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 7,883,853 | USD | |
| At 2014-06-30 | -2,933,180 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | -4,397,826 | USD | 90 |
| 2014-07-01 to 2015-03-31 | -8,972,676 | USD | 274 |
| 2014-01-01 to 2014-03-31 | -9,311,759 | USD | 90 |
| 2013-07-01 to 2014-03-31 | -9,661,976 | USD | 274 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2015-03-31 | 83,269 | USD | 274 |
| 2013-07-01 to 2014-03-31 | 15,847 | USD | 274 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | -22,238,656 | USD | |
| At 2014-06-30 | -5,421,337 | USD |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 0 | USD | 90 |
| 2013-07-01 to 2014-06-30 | 0 | USD | 365 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 86,606 | USD | |
| At 2014-06-30 | 14,526 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2015-03-31 | 1,188,988 | USD | 274 |
| 2013-07-01 to 2014-03-31 | 144,075 | USD | 274 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | -4,397,826 | USD | 90 |
| 2014-07-01 to 2015-03-31 | -8,584,778 | USD | 274 |
| 2014-01-01 to 2014-03-31 | -458,970 | USD | 90 |
| 2013-07-01 to 2014-03-31 | -802,596 | USD | 274 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 9,361,600 | USD | |
| At 2014-06-30 | 1,982,178 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 1,615,697 | USD | |
| At 2014-06-30 | 458,739 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 1,312,991 | USD | |
| At 2014-06-30 | 243,896 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 2,606,032 | USD | 90 |
| 2014-07-01 to 2015-03-31 | 4,813,747 | USD | 274 |
| 2014-01-01 to 2014-03-31 | 72,507 | USD | 90 |
| 2013-07-01 to 2014-03-31 | 95,353 | USD | 274 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 22,273,397 | shares | |
| At 2014-06-30 | 18,479,279 | shares | |
| At 2014-03-31 | 9,000,000 | shares |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2015-03-31 | 302,706 | USD | |
| At 2014-06-30 | 207,915 | USD |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | -7,397,826 | USD | 90 |
| 2014-07-01 to 2015-03-31 | -16,817,319 | USD | 274 |
| 2014-01-01 to 2014-03-31 | -9,311,759 | USD | 90 |
| 2013-07-01 to 2014-03-31 | -9,661,976 | USD | 274 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 1,791,794 | USD | 90 |
| 2014-07-01 to 2015-03-31 | 3,771,031 | USD | 274 |
| 2014-01-01 to 2014-03-31 | 386,463 | USD | 90 |
| 2013-07-01 to 2014-03-31 | 707,243 | USD | 274 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2015-03-31 | 11,189 | USD | 274 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-07-01 to 2015-03-31 | -387,898 | USD | 274 |
| 2014-01-01 to 2014-03-31 | -8,852,789 | USD | 90 |
| 2013-07-01 to 2014-03-31 | -8,859,380 | USD | 274 |
Inspect the source
- Entity
- HEPION PHARMACEUTICALS, INC. / CIK 0001583771
- Captured
- 2026-09-20T09:23:01.444Z
- SEC response SHA-256
8713b65a28b6abe1fe9df431214197b2d073688f1082552d43175ea3504e60ff
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001583771.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))